PMID- 19463894
OWN - NLM
STAT- MEDLINE
DCOM- 20090901
LR  - 20090610
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Linking)
VI  - 460
IP  - 1
DP  - 2009 Aug 21
TI  - Increased MMP-3 and CTGF expression during lipopolysaccharide-induced 
      dopaminergic neurodegeneration.
PG  - 27-31
LID - 10.1016/j.neulet.2009.05.044 [doi]
AB  - Accumulating evidence indicates that neuroinflammation contributes significantly 
      to progressive dopaminergic (DA) neurodegeneration in Parkinson's disease (PD). 
      Altered matrix metalloproteinase-3 (MMP-3) expression has been reported in 
      several neuroinflammatory paradigms; however, its relationship to 
      inflammation-induced DA neurotoxicity has not been explored. To this end, we 
      investigated the temporal expression pattern of MMP-3 and one of its downstream 
      targets, connective tissue growth factor (CTGF), following lipopolysaccharide 
      (LPS)-induced DA neurodegeneration. LPS was directly injected into the substantia 
      nigra of male Sprague-Dawley rats. Lesion formation was confirmed with 
      immunohistochemistry 48 h post-injection. MMP-3 and CTGF were measured by western 
      blot 12, 24, and 48 h post-injection. In association with neurodegeneration, 
      MMP-3 expression and activation was significantly increased 24 and 48 h after LPS 
      injection. In addition, CTGF expression increased 5-fold at the 24h time point. 
      The temporal changes in MMP-3 and CTGF expression corresponded to the 
      neurodegenerative phase of this model, suggesting that these two proteins may 
      participate in neuroinflammation-induced DA neurotoxicity.
FAU - McClain, Justin A
AU  - McClain JA
AD  - Virginia Commonwealth University, Department of Physiology and Biophysics, United 
      States.
FAU - Phillips, Linda L
AU  - Phillips LL
FAU - Fillmore, Helen L
AU  - Fillmore HL
LA  - eng
PT  - Journal Article
DEP - 20090520
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Lipopolysaccharides)
RN  - 139568-91-5 (Connective Tissue Growth Factor)
RN  - EC 1.14.16.2 (Tyrosine 3-Monooxygenase)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Animals
MH  - Brain/drug effects/metabolism/pathology
MH  - Connective Tissue Growth Factor/*metabolism
MH  - Disease Models, Animal
MH  - Lipopolysaccharides/*toxicity
MH  - Male
MH  - Matrix Metalloproteinase 3/*metabolism
MH  - Neurodegenerative Diseases/*chemically induced/*metabolism/pathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Time Factors
MH  - Tyrosine 3-Monooxygenase/metabolism
MH  - Up-Regulation/*drug effects
EDAT- 2009/05/26 09:00
MHDA- 2009/09/02 06:00
CRDT- 2009/05/26 09:00
PHST- 2009/02/04 00:00 [received]
PHST- 2009/03/27 00:00 [revised]
PHST- 2009/05/15 00:00 [accepted]
PHST- 2009/05/26 09:00 [entrez]
PHST- 2009/05/26 09:00 [pubmed]
PHST- 2009/09/02 06:00 [medline]
AID - S0304-3940(09)00668-5 [pii]
AID - 10.1016/j.neulet.2009.05.044 [doi]
PST - ppublish
SO  - Neurosci Lett. 2009 Aug 21;460(1):27-31. doi: 10.1016/j.neulet.2009.05.044. Epub 
      2009 May 20.